Located at the hometown of Nobel Laureate Albert Szent-Györgyi, the Pharmacoidea Ltd. is developing novel therapeutics for diseases with unmet medical needs. The Pharmacoidea has disposal of cutting edge technologies that can validate efficacy of its innovative therapeutics in disease-specific preclinicals models.

The company applies hit-identification, lead optimization and pre-clinical development expertise in state-of-the-art drug discovery. Pharmacoidea employs system biology approach to identify the best target molecules to tackle the disease of interest. Pharmacoidea’s discovery platform integrates in vitro, ex vivo and in vivo bioassays to identify and validate molecular targets of specific diseases. Compounds effective on in vitro targets are continuously being studied in transgenic animals, genetically modified to produce the pertinent protein validated as target in the particular disease.

Wet-lab science is carried out at Pharmacoidea’s laboratory at the National Health Institute of Szeged. With a lab space extending 100 m2 and equipped with state-of-the-art drug discovery instruments the Pharmacoidea’s team has been carrying EU-funded R&D projects in the field of drug discovery and experimental therapeutics. Pharmacoidea’s drug discovery endeavors are currently being exploited in Europe’s largest drug discovery program, the Innovative Medicines Initiative. The Pharmacoidea’s innovative assortment of drug discovery capacities are currently being exploited in collaborative R&D projects under the Innovative Medicines Initiative: COMPACT (www.compact-research.org) for the development of macromolecular-based therapeutics and AETIONOMY (www.aetionomy.eu) for the development of new therapeutic/diagnostic solutions against neurodegenerative diseases including Alzheimer’s and Parkinson’s.